Spravato for Treatment Resistant Depression: What is the success rate for Spravato? 

Depression is not always a condition that responds to the first medication prescribed. For individuals who have tried multiple antidepressants without achieving meaningful relief, the ongoing cycle of low mood, fatigue, hopelessness, loss of motivation, and impaired daily functioning can be exhausting.

What Is Spravato and How Does It Work?

Spravato is an FDA-approved prescription nasal spray containing esketamine, a medication related to ketamine. It is used in adults with treatment-resistant depression (TRD), either alone or in combination with an oral antidepressant, depending on the treatment plan.

Unlike traditional antidepressants, which primarily target neurotransmitter systems such as serotonin and norepinephrine, esketamine works through the brain’s glutamate system.

Glutamate is the brain’s primary excitatory neurotransmitter and plays an important role in learning, memory, communication between neurons, and neuroplasticity.

What Is the Success Rate of Spravato?

One of the most frequently asked questions by patients is: What percentage of people actually get better?

Clinical trials have measured treatment outcomes using two important terms: response and remission.

• Response: A reduction of at least 50% in depressive symptoms.
• Remission: Symptoms improve to a level where a person has minimal or very few remaining depressive symptoms.

In the pivotal four-week TRANSFORM clinical trials, patients receiving Spravato alongside an oral antidepressant demonstrated greater improvement in depressive symptoms than patients receiving placebo nasal spray alongside an oral antidepressant.

The results also demonstrated that Spravato does not work for everyone, and individual outcomes vary.

The clinical takeaway: Spravato offers a meaningful opportunity for improvement in treatment-resistant depression, but treatment success should be evaluated individually rather than promised through a single percentage.

What Does Success with Spravato Really Mean?

Success is not always synonymous with complete remission.

For some patients, success means waking up with less emotional heaviness. For others, it means regaining the ability to work, reconnecting with family, enjoying activities, or experiencing a renewed sense of hope.

Clinically, meaningful improvement may include:

• Reduced intensity and frequency of depressive symptoms.
• Improved motivation, energy, and concentration.
• Better sleep and emotional regulation.
• Increased ability to participate in work, relationships, and daily activities.
• Achieving sustained response or remission.
• Reduced risk of depressive relapse through continued treatment when indicated.

How Quickly Does Spravato Work?

Some patients report changes in mood or depressive symptoms within the first 24–48 hours. Clinical trials have demonstrated measurable improvement as early as the first day of treatment.

However, an early response does not necessarily mean that the full therapeutic benefit has been achieved.

Some patients experience gradual improvement over several weeks, while others require longer treatment and reassessment.

Does Spravato provide temporary relief, or can it help maintain recovery?

The SUSTAIN-1 maintenance study examined patients who had achieved stable response or remission after treatment with Spravato.

The findings demonstrated that continued treatment can significantly delay relapse in patients who have responded to Spravato.

For some individuals, benefits can be maintained over months or longer with ongoing treatment. Others may experience recurrence of symptoms and require treatment adjustments.

The goal is to identify the lowest treatment frequency that maintains meaningful clinical improvement while continuously reassessing benefits, tolerability, and patient preferences.

Final Thoughts: Redefining Hope in Treatment-Resistant Depression

For patients who have spent years trying different antidepressants without meaningful improvement, Spravato represents an important advancement in depression treatment.

Its distinct mechanism of action, potential for rapid symptom improvement, and evidence supporting relapse prevention have expanded the treatment options available for individuals living with treatment-resistant depression.

However, the true measure of success is not simply a percentage in a clinical trial.

It is the patient who begins participating in life again. The individual who reconnects with loved ones. The person who regains motivation, functioning, and a sense of possibility.

Depression treatment is not just about reducing symptoms. It is about helping people reclaim their lives.